Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -173.86% is 233% below its 5-year average of -52.25%, near the low end of its 5-year range (-173.86%–0.46%).
78.04% below its 12-month average of -97.65%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -37.88%.
RETURN ON ASSETS (ROA)
-173.86%
RETURN ON ASSETS (ROA) AVG TTM
-97.65%
RETURN ON ASSETS (ROA) AVG 3Y
-65.17%
RETURN ON ASSETS (ROA) AVG 5Y
-52.25%
RETURN ON ASSETS (ROA) AVG 10Y
-80.95%
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-78.04%
CURRENT VS 3Y AVG
-166.78%
CURRENT VS 5Y AVG
-232.77%
CURRENT VS 10Y AVG
-114.77%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-24.95%
median of 438 covered companies
CURRENT VS SECTOR MEDIAN
-596.83%
vs the sector median at left
CollPlant Biotechnologies Ltd.
Market Cap
$4.42M
Return on Assets (ROA)
-173.86%
TTM Avg
-97.65%
3Y Avg
-65.17%
5Y Avg
-52.25%
Market Cap
$4.41M
Return on Assets (ROA)
-194.09%
TTM Avg
-543.36%
3Y Avg
-310.28%
5Y Avg
-256.27%
Market Cap
$4.46M
Return on Assets (ROA)
-157.28%
TTM Avg
-221.91%
3Y Avg
-169.98%
5Y Avg
-213.74%
Market Cap
$4.32M
Return on Assets (ROA)
-94.96%
TTM Avg
-122.01%
3Y Avg
-81.62%
5Y Avg
-58.26%
Market Cap
$4.18M
Return on Assets (ROA)
N/A
TTM Avg
-140.48%
3Y Avg
-390.49%
5Y Avg
-423.69%
Market Cap
$4.79M
Return on Assets (ROA)
-28.02%
TTM Avg
-155.25%
3Y Avg
-160.56%
5Y Avg
-117.99%
Market Cap
$4.85M
Return on Assets (ROA)
-108.91%
TTM Avg
-143.36%
3Y Avg
-200.57%
5Y Avg
-146.87%
Market Cap
$3.94M
Return on Assets (ROA)
-181.89%
TTM Avg
-125.13%
3Y Avg
-74.22%
5Y Avg
-63.39%
Market Cap
$4.96M
Return on Assets (ROA)
-71.72%
TTM Avg
-29.50%
3Y Avg
-8.92%
5Y Avg
-8.92%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| CollPlant Biotechnologies Ltd. (CLGN) | $4.42M | -173.86% | -97.65% | -65.17% | -52.25% |
| Ernexa Therapeutics Inc. (ERNA)vs › | $4.41M | -194.09% | -543.36% | -310.28% | -256.27% |
| Dermata Therapeutics, Inc. (DRMA)vs › | $4.46M | -157.28% | -221.91% | -169.98% | -213.74% |
| 20/20 Biolabs Inc. (AIDX)vs › | $4.32M | -94.96% | -122.01% | -81.62% | -58.26% |
| GRI Bio, Inc. (GRI)vs › | $4.18M | N/A | -140.48% | -390.49% | -423.69% |
| Bio Green Med Solution, Inc. (BGMS)vs › | $4.79M | -28.02% | -155.25% | -160.56% | -117.99% |
| CalciMedica, Inc. (CALC)vs › | $4.85M | -108.91% | -143.36% | -200.57% | -146.87% |
| Aptevo Therapeutics Inc. (APVO)vs › | $3.94M | -181.89% | -125.13% | -74.22% | -63.39% |
| Basel Medical Group Ltd Ordinary Shares (BMGL)vs › | $4.96M | -71.72% | -29.50% | -8.92% | -8.92% |
| Gelteq Limited Ordinary Shares (GELS)vs › | $4.99M | -30.94% | -24.01% | -19.50% | -23.56% |
ROA
-173.9%
ROE
-424.9%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -106.53% |
| 2024-12-31 | -88.77% |
| 2023-12-31 | -20.57% |
| 2022-12-31 | -44.81% |
| 2021-12-31 | 0.46% |
| 2020-12-31 | -53.26% |
| 2019-12-31 | -103.83% |
| 2018-12-31 | -69.05% |
| 2017-12-31 | -71.94% |
| 2016-12-31 | -193.65% |
| 2015-12-31 | -138.51% |
| 2014-12-31 | -83.60% |
| 2013-12-31 | -52.49% |
| 2012-12-31 | -89.08% |
